PMID- 26836268
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1661-6758 (Electronic)
IS  - 1661-6499 (Linking)
VI  - 8
IP  - 4-6
DP  - 2015
TI  - Docosahexaenoic Acid-Rich Fish Oil Supplementation Improves Body Composition 
      without Influence of the PPARgamma Pro12Ala Polymorphism in Patients with Type 2 
      Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
PG  - 195-204
LID - 10.1159/000442792 [doi]
AB  - BACKGROUND: The aims of this research were to investigate (1) the impact of 
      docosahexaenoic acid (DHA)-rich fish oil supplementation on body composition, 
      plasma adiponectin level, and peroxisome proliferator-activated receptor gamma 
      (PPARgamma) gene expression, and (2) whether the effect of DHA-rich fish oil 
      supplementation on the aforementioned variables is modulated by PPARgamma Pro12Ala 
      polymorphism. METHODS: We genotyped PPARgamma Pro12Ala polymorphism in subjects with 
      type 2 diabetes mellitus (T2DM). Ala carriers and non-Ala carriers were randomly 
      assigned to DHA-rich fish oil or placebo intake for 8 weeks. RESULTS: Glycemic 
      control was not affected by the intervention. The supplementation with DHA-rich 
      fish oil decreased waist circumference (p < 0.001), body fat mass (p = 0.01), 
      body fat percent (p = 0.04), and viscera fat rating (p = 0.02) as well as trunk 
      fat mass (p = 0.04). Weight, body mass index, fat-free mass, adiponectin level, 
      and PPARgamma gene expression changes showed no significant difference. No gene-diet 
      interaction was found on body composition, adiponectin level, and PPARgamma gene 
      expression. CONCLUSIONS: DHA-rich fish oil supplementation favorably modulated 
      body composition in patients with T2DM and could be useful to reduce visceral 
      obesity. However, the PPARgamma Pro12Ala polymorphism did not influence the changes 
      in the desired variables.
CI  - (c) 2016 S. Karger AG, Basel.
FAU - Mansoori, Anahita
AU  - Mansoori A
AD  - Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of 
      Medical Sciences, Ahvaz, Iran.
FAU - Sotoudeh, Gity
AU  - Sotoudeh G
FAU - Djalali, Mahmoud
AU  - Djalali M
FAU - Eshraghian, Mohammad-Reza
AU  - Eshraghian MR
FAU - Keramatipour, Mohammad
AU  - Keramatipour M
FAU - Nasli-Esfahani, Ensieh
AU  - Nasli-Esfahani E
FAU - Shidfar, Farzad
AU  - Shidfar F
FAU - Alvandi, Ehsan
AU  - Alvandi E
FAU - Toupchian, Omid
AU  - Toupchian O
FAU - Koohdani, Fariba
AU  - Koohdani F
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160203
PL  - Switzerland
TA  - J Nutrigenet Nutrigenomics
JT  - Journal of nutrigenetics and nutrigenomics
JID - 101299758
RN  - 0 (Fish Oils)
RN  - 0 (PPAR gamma)
RN  - 0 (Placebos)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - 9DLQ4CIU6V (Proline)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Aged
MH  - Alanine/genetics
MH  - Amino Acid Substitution
MH  - Body Composition/*drug effects
MH  - Diabetes Mellitus, Type 2/*diet therapy/genetics/*metabolism
MH  - Dietary Supplements
MH  - Docosahexaenoic Acids/*administration & dosage
MH  - Double-Blind Method
MH  - Fish Oils/*administration & dosage
MH  - Humans
MH  - Middle Aged
MH  - PPAR gamma/*genetics
MH  - Placebos
MH  - *Polymorphism, Genetic
MH  - Proline/genetics
EDAT- 2016/02/03 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/02/03 06:00
PHST- 2015/06/26 00:00 [received]
PHST- 2015/11/25 00:00 [accepted]
PHST- 2016/02/03 06:00 [entrez]
PHST- 2016/02/03 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 000442792 [pii]
AID - 10.1159/000442792 [doi]
PST - ppublish
SO  - J Nutrigenet Nutrigenomics. 2015;8(4-6):195-204. doi: 10.1159/000442792. Epub 
      2016 Feb 3.